Establishment Labs signs NuSil supply extension to 2031

Automatic renewal may continue for up to five successive one-year terms unless ELSA or NuSil gives written notice by December 31 of the year before expiration.

Rhea-AI Filing Summary

Establishment Labs Holdings Inc., through its wholly owned subsidiary Establishment Labs, S.A. (ELSA), entered Amendment No. 3 to the Master Supply Agreement with NuSil Technology LLC, effective January 1, 2027. The amendment extends the initial term from December 31, 2026, to December 31, 2031, with automatic renewals for successive one-year terms, up to five, unless ELSA or NuSil provides written notice no later than December 31 of the year before the initial or then-current renewal term expires. It also revises specified provisions covering NuSil’s manufacture and sale of medical-grade silicone for specified ELSA products, payment terms, business continuity, intellectual property and pricing.

8-K Event Classification

2 items: 1.01, 9.01

2 items

Item 1.01 Entry into a Material Definitive Agreement Business

The company signed a significant contract such as a merger agreement, credit facility, or major partnership.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

Key Figures

Amendment effective date: January 1, 2027 Amended initial term end date: December 31, 2031 Automatic renewal terms: Up to five successive one-year terms

3 metrics

Amendment effective date January 1, 2027 Amendment No. 3 to the Master Supply Agreement

Amended initial term end date December 31, 2031 The prior end date was December 31, 2026

Automatic renewal terms Up to five successive one-year terms Subject to written notice by ELSA or NuSil

Key Terms

Master Supply Agreement, medical-grade silicone, business continuity

3 terms

Master Supply Agreement technical

"Amendment No. 3 to the Master Supply Agreement"

A master supply agreement is a long-term contract that sets the basic rules—price ranges, delivery schedules, quality standards, and dispute and termination terms—for future purchases between a supplier and a buyer. For investors it signals predictability in revenue, cost and supply risk—similar to a household signing a standing service contract instead of buying one-off services—so it can support more reliable financial forecasting but may also create dependency on the counterparty.

medical-grade silicone medical

"manufacture and sale of medical-grade silicone"

business continuity technical

"provisions relating to business continuity"

Business continuity is the set of plans and actions a company uses to keep essential operations running during disruptions like natural disasters, cyberattacks, or supply problems — think of it as a backup plan or spare tire for the business. Investors care because strong continuity reduces the chance of lost revenue, surprise costs, and long outages, which helps protect cash flow, reputation, and the value of their investment.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What is the term of ESTA’s amended NuSil agreement?

The amendment extends the initial term through December 31, 2031 and provides for automatic one-year renewals for up to five successive terms. ELSA or NuSil may give written notice no later than December 31 of the year before the initial or then-current renewal term expires.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 10/15/2026 - 06:07 AM EDT Accepted by SEC EDGAR 10/15/2026 - 06:01 AM EDT Learn about SEC filing dates

false 0001688757 0001688757 2026-10-14 2026-10-14 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

October 14, 2026

Date of Report (date of earliest event reported)

Establishment Labs Holdings Inc.

(Exact name of registrant as specified in its charter)

British Virgin Islands		001-38593		98-1436377
(State or other jurisdiction of		(Commission File No.)		(I.R.S. Employer
incorporation or organization)				Identification Number)

11401 Century Oaks Terrace

Suite 400

Austin, Texas 78758

(Address of principal executive offices) (Zip Code)

+1 800 924-5072

(Registrant’s telephone number, including area code)

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading symbol	Name of each exchange on which registered
Common Shares, No Par Value	ESTA	The Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2) of this chapter.

Emerging growth company ¨

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Item 1.01 Entry into a Material Definitive Agreement.

On October 14, 2026, Establishment Labs Holdings Inc. (the “Company”), through its wholly owned subsidiary, Establishment Labs, S.A. (“ELSA”), entered into Amendment No. 3 (“Amendment No. 3”) to the Master Supply Agreement (the “Agreement”), effective January 1, 2027, with NuSil Technology LLC (“NuSil”). Amendment No. 3 extends the end of the initial term of the Agreement from December 31, 2026, to December 31, 2031, with automatic renewal thereof for successive terms of one (1) year each for up to five (5) successive renewal terms, unless ELSA or NuSil provides written notice no later than December 31 of the year prior to the expiration of the initial term or the then-current renewal term. Amendment No. 3 also amends specified provisions of the Agreement relating to NuSil’s manufacture and sale of medical-grade silicone for use in specified ELSA products as well as payment terms, business continuity, and certain intellectual property and pricing provisions.

The foregoing description of Amendment No. 3 is qualified in its entirety by reference to the complete text of Amendment No. 3, a copy of which is filed hereto as Exhibit 10.1 and is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.		Description
10.1+		Amendment No. 3 to Master Supply Agreement, effective as of January 1, 2027, by and between Establishment Labs, S.A., and NuSil Technology LLC.
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

+ Certain portions of the exhibit have been redacted in compliance with Item 601(b)(10) of Regulation S-K.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized.

			ESTABLISHMENT LABS HOLDINGS INC.
Dated:	October 15, 2026	By:	/s/ Cassandra "Sandra" Harris
		Name:	Cassandra "Sandra" Harris
		Title:	Chief Financial Officer

Filing Exhibits & Attachments

4 documents

Agreements & Contracts

• EX-10.1 EXHIBIT 10.1 23.3 KB

Other Documents

• EX-101 XBRL TAXONOMY EXTENSION SCHEMA 3.0 KB
• EX-101 XBRL TAXONOMY EXTENSION LABEL LINKBASE 33.4 KB
• EX-101 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE 21.9 KB